{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"314"},{"groupId":"OG001","value":"296"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants who discontinued study treatment due to an AE is presented.","groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received Investigator's choice of paclitaxel 80-100 mg/m\\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).","id":"OG001","title":"Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 14-Mar-2022 (up to approximately 6 years)","title":"Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}